Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | PCNSL: what options are available?

Andrés Ferreri • 2 Jun 2019
ASCO 2019
Non-Hodgkin Lymphoma Methotrexate Rituximab

Andrés Ferreri, MD, of the IRCCS San Raffaele Hospital, Milan, Italy, discusses current treatment options in primary central nervous system lymphomas (PCNSL). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Andrés Ferreri

7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
1:56
Overcoming challenges in PCNCL treatment
Andrés Ferreri • 2 Jun 2019
1:55
Novel therapies for PCNSL
Andrés Ferreri • 2 Jun 2019
2:20
The challenges posed by double-hit lymphoma
Andrés Ferreri • 18 Mar 2018

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals